Cargando…

Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report

RATIONALE: Colorectal liver metastasis develops in 50% of patients diagnosed with colorectal cancer, whereas concurrent intrahepatic cholangiocarcinoma (ICC) and colorectal liver metastases is extremely rare. PATIENT CONCERNS: A 72-year-old man was referred to our hospital complaining of abdominal d...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Xiaofei, Zhao, Feng, Chen, Dong, Yang, Piao, Zhong, Weixiang, Xu, Xiangming, Wang, Weilin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320161/
https://www.ncbi.nlm.nih.gov/pubmed/30572520
http://dx.doi.org/10.1097/MD.0000000000013751
_version_ 1783385185146896384
author Cheng, Xiaofei
Zhao, Feng
Chen, Dong
Yang, Piao
Zhong, Weixiang
Xu, Xiangming
Wang, Weilin
author_facet Cheng, Xiaofei
Zhao, Feng
Chen, Dong
Yang, Piao
Zhong, Weixiang
Xu, Xiangming
Wang, Weilin
author_sort Cheng, Xiaofei
collection PubMed
description RATIONALE: Colorectal liver metastasis develops in 50% of patients diagnosed with colorectal cancer, whereas concurrent intrahepatic cholangiocarcinoma (ICC) and colorectal liver metastases is extremely rare. PATIENT CONCERNS: A 72-year-old man was referred to our hospital complaining of abdominal discomfort, diarrhea, and weakness over the last month. DIAGNOSES: Colorectal liver metastases concurrent intrahepatic cholangiocarcinoma (ICC). INTERVENTIONS: The patient was treated with mFOLFOX6 (5-fluorouracil 2400 mg/m(2), leucovorin 400 mg/m(2), and oxaliplatin 85 mg/m(2)) plus bevacizumab 5 mg/kg every 2 weeks for 2 months. However, chemotherapy was not effective for the liver S3 lesion in our case. The possibility of ICC was considered based on the multidisciplinary team (MDT) mode, together with an anomalous increase in cancer antigen 19-9 and a history of hepatolithiasis. OUTCOMES: Simultaneous resection of the colon cancer and liver tumors was performed at 6 weeks after discontinuing bevacizumab. Colorectal liver metastases concurrent ICC was confirmed by postoperative pathology. The patient's disease-free survival time is currently >14 months. LESSONS: This is the first case report of the diagnosis and timely treatment of colorectal liver metastases harboring ICC. These results suggest that multiple primary tumors should be considered as a differential diagnosis when imaging or laboratory test results are abnormal.
format Online
Article
Text
id pubmed-6320161
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-63201612019-01-14 Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report Cheng, Xiaofei Zhao, Feng Chen, Dong Yang, Piao Zhong, Weixiang Xu, Xiangming Wang, Weilin Medicine (Baltimore) Research Article RATIONALE: Colorectal liver metastasis develops in 50% of patients diagnosed with colorectal cancer, whereas concurrent intrahepatic cholangiocarcinoma (ICC) and colorectal liver metastases is extremely rare. PATIENT CONCERNS: A 72-year-old man was referred to our hospital complaining of abdominal discomfort, diarrhea, and weakness over the last month. DIAGNOSES: Colorectal liver metastases concurrent intrahepatic cholangiocarcinoma (ICC). INTERVENTIONS: The patient was treated with mFOLFOX6 (5-fluorouracil 2400 mg/m(2), leucovorin 400 mg/m(2), and oxaliplatin 85 mg/m(2)) plus bevacizumab 5 mg/kg every 2 weeks for 2 months. However, chemotherapy was not effective for the liver S3 lesion in our case. The possibility of ICC was considered based on the multidisciplinary team (MDT) mode, together with an anomalous increase in cancer antigen 19-9 and a history of hepatolithiasis. OUTCOMES: Simultaneous resection of the colon cancer and liver tumors was performed at 6 weeks after discontinuing bevacizumab. Colorectal liver metastases concurrent ICC was confirmed by postoperative pathology. The patient's disease-free survival time is currently >14 months. LESSONS: This is the first case report of the diagnosis and timely treatment of colorectal liver metastases harboring ICC. These results suggest that multiple primary tumors should be considered as a differential diagnosis when imaging or laboratory test results are abnormal. Wolters Kluwer Health 2018-12-21 /pmc/articles/PMC6320161/ /pubmed/30572520 http://dx.doi.org/10.1097/MD.0000000000013751 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Cheng, Xiaofei
Zhao, Feng
Chen, Dong
Yang, Piao
Zhong, Weixiang
Xu, Xiangming
Wang, Weilin
Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report
title Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report
title_full Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report
title_fullStr Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report
title_full_unstemmed Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report
title_short Successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: A case report
title_sort successful treatment of colorectal liver metastasis harboring intrahepatic cholangiocarcinoma: a case report
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6320161/
https://www.ncbi.nlm.nih.gov/pubmed/30572520
http://dx.doi.org/10.1097/MD.0000000000013751
work_keys_str_mv AT chengxiaofei successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport
AT zhaofeng successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport
AT chendong successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport
AT yangpiao successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport
AT zhongweixiang successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport
AT xuxiangming successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport
AT wangweilin successfultreatmentofcolorectallivermetastasisharboringintrahepaticcholangiocarcinomaacasereport